Sarepta Therapeutics (NASDAQ: SRPT) surged 41.68% in after-hours trading, hitting $25.80, up from its regular close of $18.38.
The company announced a strategic restructuring plan aimed at prioritizing high-value programs, meeting its 2027 financial obligations, and supporting long-term financial viability. Sarepta also shared updates on label revisions for ELEVIDYS, the first approved gene therapy for Duchenne muscular dystrophy, along with preliminary financial results for the quarter ended June 30, 2025.
During regular trading on Wednesday, July 16, 2025, SRPT stock fluctuated between $17.85 and $18.54, starting the day at $18.30 with a volume of 2.90 million shares.
